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Abstract 
Hematopoietic stem cells (HSC) undergo expansion and differentiation giving rise to all 
terminally differentiated blood cells throughout life.  HSC are found in distinct 
anatomical sites during development, and in adults, hematopoiesis occurs 
predominantly on the luminal side of the bone cavity in bone marrow.  Millions of 
newly formed blood cells are generated per second to accommodate the short half-life of 
hematopoietic cells. In order for this to happen, HSC must sustain their self-renewal 
capacity as well as their capability to commit and differentiate towards multiple cell 
lineages. Development of the hematopoietic system is finely regulated as the animal 
ages, so that it does not become exhausted or misdirected. This review covers aspects of 
hematopoietic development from the embryonic period through adult life in relation to 
development of dendritic cells (DC).  It also considers a role for HSC in extramedullary 
sites and their possible role in myelopoiesis with formation of tissue-specific antigen 
presenting cells (APC). 
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EARLY HEMATOPOIESIS 
The hematopoietic and cardiovascular organ systems are the first to emerge during 
embryogenesis because the embryo requires a functional heart, vascular system, and blood 
for survival and growth in the early post-implantation period.  Blood cell development in the 
embryo depends on gastrulation and mesoderm formation.  Mesodermal cells contribute to 
the heart, the aorta in the embryo proper, formation of hematopoietic cells in yolk sac and 
vascular interconnection in the embryo.1 Embryonic hematopoiesis in mice begins after 
gastrulation at embryonic day 6 (E6), when mesodermal cells commit to becoming 
hematopoietic cells.2 The sequential sites for hematopoiesis during embryonic development 
then include yolk sac, the aorta-gonad-mesonephros (AGM) region, placenta, fetal liver, 
spleen, and finally bone marrow.3 
Yolk sac, a bilayer structure of mesoderm and endoderm-derived cell layers, is the initial 
site for blood cell formation.  The first hematopoietic precursors derive from mesoderm that 
gives rise to the hemangioblast, a bipotential precursor for blood and endothelium that enters 
the yolk sac to initiate primitive hematopoiesis across E7-E7.5.  Blood cells produced at this 
time are primitive hematopoietic cells consisting mainly of large nucleated red blood cells.4 
The presence of definitive hematopoietic progenitors then marks the start of a second wave of 
blood cell production on day E8.5.5 However, the microenvironment in the yolk sac does not 
support the differentiation of definitive hematopoietic progenitors.  These therefore exit the 
yolk sac via the vitelline veins.  Following transient appearance in the AGM region, HSC are 
seen to colonize fetal liver passing through umbilical cord vessels of the placenta where they 
contribute to robust expansion and definitive hematopoiesis.  
HSC then appear in the fetal liver at E11.5 where they undergo proliferation and 
differentiation, with maximum expansion of HSC across E15.5-E16.5, followed by a decline 
in cell numbers.6 CFU-E and proerythroblasts prevail in early fetal liver, whereas myeloid 
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and lymphoid progenitors accumulate at later stages.  Modification of the liver 
microenvironment during fetal development occurs in preparation for HSC expansion and 
lineage differentiation7, consistent with phenotypic changes in HSC across different 
developmental stages.8  
Bone development begins at E12.5 as mesenchymal condensations are observed.  Briefly, 
mesenchymal progenitor cells first give rise to chondrocytes that create a cartilaginous 
framework for bone.  Chondrocytes are later replaced by osteoblastic cells that build up 
calcified bone through endochondral ossification to form the bone marrow cavity.9 Vascular 
invasion into the bone then facilitates the circulation and seeding of HSC.  Clonogenic 
hematopoietic activity in bone marrow can be found at ~E17.5 and persists throughout 
postnatal life.10   	  
Hematopoiesis in fetal spleen occurs from E13 until the first weeks of the postnatal 
period.  Hematopoietic progenitors from fetal liver migrate to fetal spleen at E13-E14 and 
undergo proliferation and differentiation to give mature blood cells.  In contrast to fetal liver, 
fetal spleen does not have significant hematopoietic activity.11 Hematopoiesis in fetal liver 
depends on expansion of progenitors, while hematopoiesis in fetal spleen relies on immediate 
hematopoietic precursors derived from fetal liver which home directly to spleen.  Special 
microenvironments or niches in fetal spleen appear to restrict or favor the development of 
particular blood cell lineages.12 
      
PROPERTIES OF HEMATOPOIETIC STEM CELLS  
In adult humans, bone marrow is the major hematopoietic organ producing more than 109 
mature blood cells per day.  Due to the short half-life of mature cells, continuous production 
of cells depends on the ability of HSC to self-renew and differentiate to give all blood cell 
types.13 In the steady-state, specialized niches in bone marrow provide an optimal 
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microenvironment for maintenance of HSC by regulation of their self-renewal and 
differentiative capacity, and conservation of their multipotency throughout cell division.14   
Self-renewal is driven intrinsically by gene expression and modulated through HSC 
interaction with extrinsic cues in the environment.  HSC niches are crucial regulators which 
determine whether symmetric or asymmetric cell division occurs.15 During asymmetric 
division, HSC form a daughter cell and another HSC.  Asymmetric division has been 
described for several tissue-specific stem cells, and several cell fate regulators including 
Notch, HoxB4, and Sonic hedgehog have been shown to play a role in the self-renewal 
process.16-19 Wnt signaling is important for self-renewal because induced expression of a 
frizzled ligand-binding domain, an inhibitor of the Wnt signaling pathway, leads to inhibition 
of HSC growth in vitro.20 
Lineage commitment is the process by which HSC become restricted in their 
differentiation and develop into a fully committed progenitor of a single blood cell lineage.21 
All murine adult hematopoietic cells derive from the multipotential HSC.  This single cell 
type can restore the mature peripheral population of hematopoietic or blood cells in lethally 
irradiated recipient mice via bone marrow transplantation.  Murine HSC were first 
characterized by their lack of lineage (Lin) specific antigens, their expression of Sca-1 (stem 
cell associated antigen) and c-Kit, and low expression of Thy-1.22 This subset was later 
classified as the Lin-Sca-1+c-Kit+ compartment (LSK).  Within the HSC hierarchy, LSK 
represent a diverse group which can be classified as long-term self-renewing HSC (LT-HSC), 
shortterm, or transiently, self-renewing HSC (ST-HSC), and multipotential progenitors 
(MPP).23, 24 
LT-HSC have capacity for life long reconstitution of the hematopoietic system.  In mice, 
they are highly enriched in the LSK-Thy1.1lo cell fraction that can be further purified as Flk-
2- cells.25 The CD150, CD244 and CD48 signaling lymphocyte activation molecules have 
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recently been found to discriminate HSC subpopulations such that, LSKCD150+CD48-
CD244-CD34- cells are defined as HSC, LSKCD150-CD48-CD244+CD34- as MPP, and 
LSKCD150-CD48+CD244+ as more committed progenitors.26-28 
A hierarchy of hematopoietic cell differentiation continues to be established using both 
cell surface marker analysis and in vitro colony forming and functional assays.  HSC, as 
multipotent progenitors, sit at the top of the hierarchy and possess high capacity for self-
renewal and differentiation.  Downstream on the hierarchy, HSC lose their self-renewing 
ability and develop into MPP that give rise to several lineages of blood cells.25 MPP represent 
a heterogeneous population of stem/progenitor cells, and remain under investigation in terms 
of their subsets and their differentiative potential.26, 29-31  
In terms of differentiation to give a diversity of APC, the myeloid pathway is of particular 
interest. HSC give rise to common myeloid progenitors (CMP) and common lymphoid 
progenitors (CLP) through a multipotential progenitor (MPP).31, 32 CMP then differentiate to 
give granulocyte-macrophage progenitors (GMP) and megakaryocyte-erythroid progenitors 
(MEP).  GMP are the progenitors of granulocytic and macrophage/monocytic cells including 
neutrophils, eosinophils, basophils, and monocytes. MEP give rise to red blood cells and 
megakaryocytes. CLP give rise to lymphoid and NK cell progenitors, followed by generation 
of mature T cells, B cells and NK cells.  The Flt3+ subset of CMP and CLP give rise to 
dendritic cells (DC).33 Two further progenitors have recently been defined in relation to DC 
development (Figure 1).  The earliest is the MDP, a myeloid dendritic progenitor which 
overlaps with the CMP and CLP, but not the GMP population.34, 35 A downstream common 
dendritic progenitor (CDP) which responds to Flt3L has been identified as a specific 
progenitor of conventional (c)DC and plasmacytoid (p)DC.36, 37 The relationship between 
CDP and the previously defined CLP, CMP and MDP populations is still under investigation.  
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HSC ARE DISTRIBUTED AND NOT RESTRICTED TO BONE MARROW 
Bone marrow primarily provides niches for HSC seeding and contributes the 
microenvironment which supports self-renewal and differentiation. In the adult, HSC 
migration from BM into the bloodstream in the steady-state is important for maintaining 
homeostasis. Collection of stem cells for transplantation in a clinical setting takes advantage 
of this natural migratory phenomenon by enforcing the release, or by ‘mobilising’ HSC, from 
bone marrow by infusion of chemotherapeutic drugs or cytokines like granulocyte-colony 
stimulating factor (G-CSF). HSC can then be collected from blood for stem cell 
transplantation.  Adoptive transfer then leads to reconstitution of all hematopoietic cells after 
HSC home to and infiltrate bone marrow.  One enigma is that HSC introduced into the 
peripheral blood circulation can traffic back into lymphatic circulation and into bone marrow, 
and so find their niches in this tissue (Figure 2).38 It is also clear that following intravenous 
infusion, HSC localize in spleen and other extramedullary tissue niches (Figure 2).38 
Several mechanisms are known to regulate HSC homing into niches.  CXCL12 or stroma-
derived factor-1 (SDF-1) and its receptor CXCR4 are master regulators of HSC migration 
through blood during embryonic development, consistent with reduction of myeloid 
progenitors in CXCR4-/- and CXCL12-/- mice.39, 40 HSC also use VLA-4 (integrin α4β1) to 
localise themselves in contact with blood vessels in bone marrow via binding to VCAM-1 
expressed on bone marrow stromal or endothelial cells (Figure 2).41 Migration of HSC into 
extramedullary hematopoietic organs such as spleen and liver is also mediated via interaction 
of VLA-4 with VCAM-1, ahead of returning to the appropriate niche that secretes SDF-1 
(CXCL12) (Figure 2).41      
Studies now show that HSC can enter and circulate through the lymphatic system.  The 
egress of HSC from bone marrow into extramedullary tissues depends on sphingosine-1-
phosphate receptor (S1P1) (Figure 2).  HSC also use S1P1, to migrate across lymphatic 
	   8	  
vessels and so restore specialized myeloid cells in peripheral tissues.42 HSC express toll-like 
receptors (TLR), and their co-receptors MD-2 and CD14, required for recognition of 
pathogen associated molecular patterns such as bacterial lipopolysaccharide (LPS).43 
Interaction of TLR with LPS signals myeloid differentiation in migratory HSC localized in 
peripheral tissues.  LPS was found to amplify the differentiation of HSC in local tissues, and 
to reduce the expression of S1P1 on HSC, so leading to retention of HSC within tissue sites.42  
During inflammatory responses, the phagocytic activity of sinusdoidal-lining 
macrophages is dramatically increased in order to remove invading pathogens.  During 
inflammation, HSC protect themselves from macrophage uptake by upregulating CD47, an 
immunoglobulin-like protein which interacts with integrins and thrombospondins to protect 
HSC from reactive phagocytosis.44-46 CD47 interacts with its receptor, SIRPα on 
macrophages and dendritic cells, to prevent phagocytosis, so ensuring survival of HSC during 
inflammation.44, 45    
 
NICHES FOR HEMATOPOIESIS ARE DISTRIBUTED 
Several niches have been described as sites for HSC maintenance, including endosteum of 
bone and vascular niches in bone marrow and spleen.47, 48 In adult mice, the majority of HSC 
reside within osteoblastic and vascular niches in bone marrow where most hematopoietic 
activity occurs, whilst smaller numbers reside in vascular niches in other tissues.  
Bone marrow niches contain specialized cells that provide membrane-bound and secreted 
growth factors to support HSC growth.49, 50 Many studies have focused on the role of 
endosteal cells lining the inner surface of bone at the interface with bone marrow, in HSC 
maintenance.14, 51-54 Endosteal cells differentiate into osteoblasts which support cell-to-cell 
contact with HSC, mediated through multiple adhesive interactions including homotypic 
interactions involving N-cadherin (Figure 2). Osteopontin (OPN) induces HSC retention and 
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quiescence in the bone marrow by binding to several integrins or to CD44, resulting in 
downregulation of Jagged1 expression on stromal cells and Notch1 expression on HSC.55  
Endosteal cells produce growth factors like stem cell factor (SCF) which support HSC 
function and survival (Figure 2). Angiopoietin (Ang-1) and thrombopoietin (TPO) promote 
quiescence of HSC, while SDF-1 (CXCL12) regulates migration of HSC within the bone 
marrow.56-58 The endosteum also comprises the bone resorbing osteoclasts and a balance 
between osteoblastic and osteoclastic activities in the bone marrow is important for 
development of HSC.59   
The highly vascularised nature of the endosteum is also consistent with endothelial cells 
having a critical role in regulation of HSC development in bone marrow.50 Vascular niches 
are considered alternate sites for HSC maintenance. During embyogenesis, HSC arise from 
progenitors located in perivascular sites, and HSC in extramedullary tissues like liver and 
spleen are located in sinusoidal or vascular areas in the absence of osteoblastic cells. 
Lifelong maintenance of the HSC pool depends on protecting HSC from premature 
exhaustion under conditions of stress.  Quiescence in terms of cell cycle is a common 
property of niche-associated HSC. Although HSC divide infrequently, the entire HSC pool 
turns over every few weeks.  In mice, dormant HSC divide every 145 days or 5 times per 
lifetime.28 These multilineage long-term self-renewing cells create a silent reservoir of HSC 
during homeostasis. Upon stimulation with G-CSF, dormant HSC enter cell cycle, and then 
switch back to dormancy. HSC can reversibly undergo self-renewal under conditions of 
stress.28 Quiescence is maintained by signaling within the niche, which induces the Tie-2 
tyrosine kinase receptor on HSC which interacts with angiopoietin-1 (Ang-1) on 
osteoblasts57, as well as the TPO/Mpl and Wnt/β-catenin signaling interactions, also 
important for HSC quiescence (Figure 2).60   
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Vascular conduits are the major highways by which hematopoietic cells and 
hematopoietic progenitors traffic to liver and spleen in adults.61-63 It is generally accepted that 
a small number of hematopoietic progenitors circulate through peripheral sites and then home 
back to the bone marrow.64, 65 Consistent with HSC migration, several studies have identified 
hematopoietic progenitors in heart.66-68 Indeed, c-kit+ cells isolated in the heart after 
myocardial infarction have been reported to have a bone marrow origin69-71.  Hematopoietic 
progenitors from bone marrow can give rise to microglia following transplantation into 
brain.72, 73 After brain injury it is possible that HSC or other hematopoietic progenitors from 
bone marrow may enter the brain and differentiate to become APC. There are also reports of 
the presence of hematopoietic progenitors in peripheral tissue sites like kidney74, skin75, and 
intestinal tract.76 Such progenitors can give rise to hematopoietic cells specific to each tissue 
site.  Similarly, Langerhans cells in skin derive from self-renewing hematopoietic progenitors 
which colonise the epidermis during embryonic development.77  
 
HEMATOPOIESIS LEADING TO A DISTRIBUTED PATTERN OF MYELOID AND 
DENDRITIC CELLS IN MULTIPLE TISSUES 
Hematopoiesis leading to APC formation now appears to reflect a complex set of 
developmental pathways originating from progenitors in bone marrow, leading to a diverse 
range of cells in different states of development within tissue sites such as bone marrow, 
liver, spleen and other lymphoid and non-lymphoid organs.78 DC emerge from bone marrow 
progenitors, but the exact progenitors that give rise to DC and how they relate to known 
progenitors of lymphoid and myeloid cells in vivo is still under investigation (Figure 1). 
Recent developmental studies show that DC subsets and monocytes/macrophages are 
generated along a myeloid pathway.34, 79 Data from parabiotic mice also support the 
hypothesis that lymphoid tissue DC and monocytes share a common bone marrow-derived 
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macrophage/dendritic progenitor (MDP), identified as a Lin-Sca1-c-
KithiCD115+CX3CR1+Flt3+ subset also expressing CD34 and CD16/32.35, 80 A more 
committed, distinct bone marrow progenitor called the common DC progenitor (CDP) has 
been identified as a Lin- Sca1+c-KitloCD115+Flt3+ subset which gives rise cDC and pDC 
(Figure 1).35, 37 Data such as these supports the concept that development of monocytes and 
macrophages is separated from that of DC before these cell types migrate into peripheral 
lymphoid tissues.   
Multiple DC subsets have now been identified in tissues around the body.  Their immune 
capacity varies in terms of ability to take up antigen and presence of inflammatory stimuli. In 
thymus, DC derive from an intrathymic lymphoid progenitor and represent a specialized 
subset important in creating a self-tolerant T cell repertoire78. In murine spleen, several 
subsets are recognized including cDC and pDC (Figure 1), each phenotypically and 
functionally distinct. Conventional DC are small, non-granular cells comprising two subsets 
of CD8α+ and CD8α- cDC.81 Counterpart cells can also be found in humans, free of infection 
and inflammation.82 The majority of DC in spleen are CD8α- cDC with only ~20% cDC of 
CD8α+ phenotype.83 The CD8α+ cDC are localised in the T-cell rich areas or periarteriolar 
lymphatic sheath (PALS) of spleen, while the CD8α− cDC are found in the marginal zone.  
CD8α− cDC can migrate into the T-cell zone upon activation with bacterial 
lipopolysaccharides (LPS).84, 85 Plasmacytoid DC have strong capacity to secrete type-1 
interferon (IFN-α) upon viral or bacterial infection, and express CD11c, B220, CD36, CD4, 
CD68, and MHC-II on their cell surface.  The function of pDC is linked to their expression of 
TLR-7 and TLR-9 which detect viral nucleic acid in early endosomes.86  
Monocytes can also be induced to differentiate in vitro under the influence of 
inflammatory cytokines like GM-CSF and TNF-α to give monocyte-derived DC (mo-DC). 
These have been commonly studied as a model DC type and used in intervention or 
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immunotherapy against malignancies.  However, DC produced by this protocol represent 
inflammatory DC, and are distinct from steady-state cDC. It is not yet clear whether mo-DC 
correspond to any DC subsets in steady-state lymphoid organs.87 Other myeloid subsets 
described in spleen include TNF/iNOS-producing (Tip) DC88 and inflammatory monocytes.89 
In general, DC exist in peripheral tissues in an immature state and possess high capability 
for capturing and processing antigens from the local environment.  After endocytosis of 
foreign antigens, these immature DC in peripheral tissues migrate to lymphoid organs where 
they undergo antigen processing and cell maturation, whereby DC upregulate co-stimulatory 
molecules like CD40, CD69, CD80, and CD86.  Mature DC possess high capacity for 
presentation of antigen to naïve T lymphocytes90, 91, and have high capability for cross 
presentation of endocytosed antigen for subsequent CD8+ T cell activation.92 Presentation of 
antigenic peptides by DC expressing appropriate co-stimulatory molecules results in 
activation of T cells for immunogenic responses, while antigen presentation without co-
stimulation leads to T cell activation for tolerogenic responses.93, 94 A wide range of DC 
subsets are therefore formed which act as extremely important central controllers of tolerance 
and immunity. 
 
EXTRAMEDULLARY SITES FOR MYELOPOIESIS OF DC 
DC can also develop within peripheral tissue sites and this has clearly been demonstrated for 
Langerhans cells. Cells of host origin were found several months after bone marrow 
transplantation77, indicating that skin Langerhans cells are derived from tissue-restricted 
myeloid progenitors.  Thus, DC development from progenitors within peripheral tissue sites 
might be possible given the distribution of HSC within tissues, and the potential for 
hematopoietic niches in multiple tissue sites. However, the extent to which this happens is 
not yet fully understood. In particular, spleen appears to support extramedullary 
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hematopoiesis for development of tissue-specific APC. In humans and mice, steady state-
spleen contains cDC and pDC which are maintained by the replenishment of pre-DC, or 
precursors of cDC and pDC which derive from progenitors in bone marrow.  We now present 
evidence that distinct dendritic-like cells appear to arise in spleen from endogenous self-
renewing progenitors (Figure 1).95  
In vitro studies from this lab showed that continuous long-term stromal cultures (LTC) of 
spleen support production of distinct dendritic-like cells which are large cells expressing 
CD11c, CD11b, and MHC-I, but not MHC-II.96 Since these cells resembled immature 
myeloid DC, they were named LTC-DC.96-100 The phenotype of cells produced has remained 
stable over years of culture with characteristic expression of CD11c, CD11b, CD80, CD86, 
MHC-I, CD205 but not MHC-II CD8α or B220.96, 100 Gene expression studies have shown 
that LTC-DC express genes encoding several cell surface molecules expressed by DC.101, 102 
LTC are distinct from other in vitro cultures for DC production in that stromal cells support 
DC production without addition of exogenous inflammatory cytokines, reflecting the capacity 
of the spleen stromal cells to support DC haematopoiesis.103 The continual production of 
immature myeloid DC in LTC led to the hypothesis that hematopoietic stem or progenitor 
cells are maintained within LTC.104, 105 Ongoing investigations have now supported that 
hypothesis.  
Recently it was shown that LTC-DC have an in vivo counterpart cell, distinguishable 
from other DC subtypes on the basis of marker expression.106 These cells are distinct from 
cDC by their higher endocytic activity, absence of MHC-II expression, and their RelB-
independent development.107, 108 They are also phenotypically and functionally distinct from 
monocytes.106  The in vivo counterpart of LTC-DC, termed ‘L-DC’ has now been identified 
in both adult and neonatal spleen, and these cells possess highly endocytic activity, and can 
cross-present antigens to CD8+ T cells, with very limited ability to stimulate CD4+ T cell 
	   14	  
responses.106 The inability of L-DC to induce a helper T cell response is likely due to the 
absence or low MHC-II expression on these cells.100 LTC-DC and L-DC are readily 
distinguished from monocytes which cannot cross-present antigen to CD8+ T cells.105, 106 
 Hematopoietic progenitors in LTC and their counterparts in vivo have been investigated 
in order to substantiate the development of L-DC as a distinct APC in the context of the 
spleen microenvironment.  Based on the finding that a population of small cells is maintained 
in LTC, which reflect Lin-c-kit+Sca-1+ progenitors109, the question was raised as to whether 
HSC or MPP could serve the role as L-DC progenitors in spleen.95  HSC derived from 
spleen104 and bone marrow105 have now been shown to act as progenitors of L-DC in LTC.   
When these same subsets of HSC from spleen or bone marrow were adoptively transferred 
into lethally irradiated mice there was a bias favouring production of L-DC over other DC 
subsets in spleen.104, 105 These data raise the possibility that APC can develop in spleen from 
endogenous self-renewing HSC and have tissue-specific function perhaps related to blood-
borne antigens. Further studies are underway to gain complete understanding of the 
development of this putative novel DC subset in the splenic context.  
 
CONCLUSION 
Indeed, there is much to be learned about tissue niches for HSC and about tissue-specific 
hematopoiesis for production of APC, before their importance in tissue-specific inflammation 
and immunity can be interpreted and considered in terms of immunotherapy.  Indeed, a role 
for self-renewing tissue-specific progenitors in production of tissue-specific APC during the 
steady-state and during inflammation can be justified in terms of tissue-specific immunity 
reflecting some level of diversification and compartmentalisation of the immune response.  
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Figure Legends 
Figure 1 Myelopoiesis leading to dendritic cell development. The bone marrow maintains 
hematopoietic stem cells (HSC).  Myeloid cells are produced from a downstream 
common myeloid progenitor (CMP). These further differentiate to give 
macrophage/dendritic progenitors (MDP) which are precursors of monocytes, 
macrophages and dendritic cells. Recently a common dendritic progenitor (CDP) was 
shown to give restricted development of splenic DC via a precursor detectable in both 
blood and spleen. A novel antigen presenting cell type has been characterized in 
murine spleen. These dendritic-like cells have been named ‘L-DC’ and appear to 
derive by direct differentiation from HSC in bone marrow and spleen.         
Figure 2 The bone marrow microenvironment provides signals which control HSC self-
renewal, migration, and quiescence. (A) HSC migrate within the niche by interaction 
of SDF-1 (CXCL12) produced by osteoblasts (OB) with CXCR4 on HSC. HSC are 
maintained on the endosteal surface of bone through cell-cell interactions, including 
homotypic interactions involving N-cadherin, and osteopontin (OPN) interaction with 
CD44 or integrins. Osteopontin supports retention of HSC in the niche by down 
regulation of Jagged-1 expression which interacts with Notch-1 on HSC. These 
interactions allow Tie-2 on HSC to interact with angiopoietin (Ang-1), and cKit to 
interact with stem cell factor (SCF) on the surface of osteoblasts. Angiopoietin (Ang-
1) and thrombopoietin (TPO) interactions with their receptors on HSC supports HSC 
quiescence. (B) HSC migrate from blood into extramedullary tissues via a 
sphingosine-1-phosphate (S1P) gradient. The interaction of S1P with its receptor 
(S1P1), in combination with other molecules such as CXCR4 and VLA-4 which 
interact with ligands on endothelial cells (EC) (CXCL12 and VCAM-1), facilitates 
HSC migration into extramedullary tissues. The S1P level in tissues is lower due to 
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S1P lyase activity. This results in localization of HSC within tissue niches for 
differentiation. HSC can also enter lymphatic tissues including bone marrow through 
the guidance of S1P. 
 


